Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGF2 | P09038 | 1/20 | 0.43 |
| ▸ | MDK | P21741 | 1/20 | 0.43 |
| ▸ | NT5E | P21589 | 1/20 | 0.42 |
| ▸ | PTPN1 | P18031 | 14/20 | 0.39 |
| ▸ | PTPN2 | P17706 | 4/20 | 0.38 |
| ▸ | PTPN11 | Q06124 | 3/20 | 0.38 |
| ▸ | PTPN6 | P29350 | 2/20 | 0.38 |
| ▸ | LGALS3 | P17931 | 1/20 | 0.38 |
| ▸ | GJB2 | P29033 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17087719 | 0.90 | FGF2 (0.37) | FGF2MDKNT5EPTPN1PTPN2 | |
| SCHEMBL20243571 | 0.88 | LGALS3 (0.38) | FGF2MDKNT5EPTPN1PTPN2 | |
| SCHEMBL24059832 | 0.88 | LGALS3 (0.38) | FGF2MDKNT5EPTPN1PTPN2 | |
| SCHEMBL22013736 | 0.84 | NT5E (0.47) | NT5EPTPN1PTPN2PTPN11PTPN6 | |
| SCHEMBL24059833 | 0.84 | NT5E (0.47) | NT5EPTPN1PTPN2PTPN11PTPN6 | |
| SCHEMBL18394464 | 0.84 | NT5E (0.47) | NT5EPTPN1PTPN2PTPN11PTPN6 | |
| SCHEMBL18412646 | 0.83 | PTPN1 (0.36) | FGF2MDKNT5EPTPN1PTPN2 | |
| SCHEMBL18412656 | 0.82 | LGALS3 (0.37) | FGF2MDKNT5EPTPN1PTPN2 | |
| SCHEMBL13008540 | 0.78 | FGF2 (0.44) | FGF2MDKNT5EPTPN1PTPN2 | |
| SCHEMBL18412655 | 0.78 | FGF2 (0.36) | FGF2MDKNT5EPTPN1PTPN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10662212-B2 | Carbohydrate ligands that bind to IGM antibodies against myelin-associated glycoprotein | UNIVERSITAT BASEL (CH) | 2020-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10662212-B2 | Carbohydrate ligands that bind to IGM antibodies against myelin-associated glycoprotein | MAG, PMP22, SIGLEC7 | FGF2 1865/4885MDK 51/4885NT5E 1622/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.